Edition:
India

Epizyme Inc (EPZM.OQ)

EPZM.OQ on NASDAQ Stock Exchange Global Select Market

12.65USD
17 Nov 2017
Change (% chg)

$-0.25 (-1.94%)
Prev Close
$12.90
Open
$12.90
Day's High
$12.90
Day's Low
$12.55
Volume
63,177
Avg. Vol
143,114
52-wk High
$20.40
52-wk Low
$9.35

Chart for

About

Epizyme, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of... (more)

Overall

Beta: 2.21
Market Cap(Mil.): $1,257.42
Shares Outstanding(Mil.): 67.79
Dividend: --
Yield (%): --

Financials

BRIEF-Epizyme announces pricing of public offering of common stock

* Epizyme announces pricing of public offering of common stock

14 Sep 2017

BRIEF-Epizyme reports Q2 loss of $0.48/shr

* Epizyme reports second quarter 2017 financial results and clinical and business progress

04 Aug 2017

BRIEF-US Oncology Research and Epizyme establish collaboration to identify non-hodgkin lymphoma patients with EZH2 mutations

* US Oncology Research and Epizyme establish collaboration to identify non-hodgkin lymphoma patients with EZH2 mutations

01 Aug 2017

BRIEF-Epizyme announces Tazemetostat to be evaluated in NCI-COG pediatric MATCH trial

* Epizyme announces Tazemetostat to be evaluated in NCI’s recently initiated NCI-COG pediatric MATCH trial Source text for Eikon: Further company coverage:

25 Jul 2017

BRIEF-Epizyme expands clinical collaboration with Genentech

* Epizyme expands clinical collaboration to study tazemetostat and tecentriq® combination in nsclc

26 Jun 2017

BRIEF-Epizyme announces tazemetostat granted orphan drug designation

* Epizyme announces tazemetostat granted orphan drug designation for the treatment of soft tissue sarcoma Source text for Eikon: Further company coverage:

21 Jun 2017

BRIEF-Epizyme reports positive interim data from Phase 2 trial for tazemetostat

* Epizyme reports positive interim data from Phase 2 trial for tazemetostat in relapsed or refractory follicular lymphoma and dlbcl patients

14 Jun 2017

Competitors

  Price Chg
Eisai Co., Ltd (4523.T) ¥6,389 0.00
Novartis AG (NOVN.S) CHF83.30 --
GlaxoSmithKline plc (GSK.L) 1,308.00 --
Celgene Corporation (CELG.OQ) $104.10 +0.75

Earnings vs. Estimates